IMVT Share Price | Immunovant, Inc. Stock Analysis & Recommendation

Q: How big is Immunovant, Inc.?

Market Cap: As of Jun 18, Immunovant, Inc. has a market capitalization of 2,616.83 million, categorizing it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Immunovant, Inc. reported net sales of 0.00 million and a net profit of -413.84 million.Balance Sheet Snapshot: As of Mar 25, the company reported shareholder's funds of 707.45 million and total assets of 777.32 million.

Q: What does Immunovant, Inc. do?

Overview: Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for patients with autoimmune diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.Financial Snapshot: Most recent Net Profit: -106 Million (Quarterly Results - Mar 2025) Market cap: USD 2,616.83 Million (Mid Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -58.50% Price to Book: 3.70Contact Details: Address: 320 West 37Th Street, NEW YORK NY: 10018 Tel: 1 917 5803099 Fax: 1 302 6365454 Website: https://immunovant.com/

Q: Is Immunovant, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Immunovant, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a mildly bullish stance for both weekly and monthly periods. Daily moving averages are bullish, suggesting positive momentum. However, the KST shows a mixed signal with a bullish weekly and bearish monthly reading. The Dow Theory indicates no trend in both weekly and monthly time frames.In terms of performance, Immunovant has outperformed the S&P 500 over the past week and month, with returns of 12.88% and 43.14%, respectively, compared to the S&P 500's 0.71% and 1.92%. However, it has underperformed over the year and five years. Overall, the current technical stance is mildly bullish, supported by several indicators, despite mixed signals in some areas.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

338.75 k

Shareholding (Dec 2025)

FII

4.31%

Held by 130 FIIs

DII

73.18%

Held by 34 DIIs

Promoter

0.08%

How big is Immunovant, Inc.?

22-Jun-2025

As of Jun 18, Immunovant, Inc. has a market capitalization of $2.62 billion, with net sales of $0.00 million and a net profit of -$413.84 million over the last four quarters. The company reported shareholder's funds of $707.45 million and total assets of $777.32 million as of Mar 25.

View full answer

What does Immunovant, Inc. do?

22-Jun-2025

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases, with a market cap of approximately $2.62 billion and a recent net profit of -$106 million. The company has no dividend yield and is currently loss-making.

View full answer

Who are in the management team of Immunovant, Inc.?

22-Jun-2025

As of March 2022, the management team of Immunovant, Inc. includes Dr. Frank Torti (Chairman), Dr. Peter Salzmann (CEO), Dr. Eric Venker, and several independent directors: Andrew Fromkin, Douglas Hughes, George Migausky, and Atul Pande. They oversee the company's strategic direction and operations.

View full answer

Is Immunovant, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Immunovant, Inc. shows a mildly bullish trend with positive momentum indicators, having outperformed the S&P 500 recently, despite mixed signals in some technical aspects.

View full answer

Compare Immunovant, Inc. with Similar Stocks

Vaxcyte, Inc.Halozyme Therapeutics, Inc.Elanco Animal Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5,088 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-47.07%

Price to Book

5.16

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-111 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-7.89%

6 Months

60.16%

1 Year

27.37%

2 Years

-23.11%

3 Years

62.15%

4 Years

329.12%

5 Years

59.43%

Immunovant, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-223.62%

EBIT to Interest (avg)

-258.75

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

0.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

57.19%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.16

EV to EBIT

-8.40

EV to EBITDA

-8.41

EV to Capital Employed

-487.94

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-47.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 63 Schemes (22.44%)

Foreign Institutions

Held by 130 Foreign Institutions (4.31%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.45% vs -116.15% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-114.30",
          "val2": "-114.20",
          "chgp": "-0.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-110.60",
          "val2": "-111.10",
          "chgp": "0.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -59.58% vs -22.89% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-437.80",
          "val2": "-270.00",
          "chgp": "-62.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-12.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-413.80",
          "val2": "-259.30",
          "chgp": "-59.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-114.30

-114.20

-0.09%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-110.60

-111.10

0.45%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 0.45% vs -116.15% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-437.80

-270.00

-62.15%

Interest

0.00

Exceptional Items

0.00

-12.50

100.00%

Consolidate Net Profit

-413.80

-259.30

-59.58%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -59.58% vs -22.89% in Mar 2024

All Annual Results

Company CV

About Immunovant, Inc.

Immunovant, Inc.

Pharmaceuticals & Biotechnology

Immunovant, Inc., formerly Health Sciences Acquisitions Corp, is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. It is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn).

Company Coordinates

Company Details

320 West 37Th Street , NEW YORK NY : 10018

Tel: 1 917 5803099

https://immunovant.com/

Registrar Details